Shares of Alvotech (ALVO have increased by 4% on Monday following news that its commercialization partner in Japan, Fuji Pharma Co., Ltd., has received approval to market AVT04 (ustekinumab), a biosimilar to Stelara, from the Japanese Ministry of Health, Labor and Welfare.